8-K current report · filed Nov 10, 2026

Scholar Rock Holding Corp (SRRK) 8-K Current Report: November 10, 2026

Item 1.01Item 2.02Item 7.01Item EX-99.1Item EX-99.2SRRK overview

Short answer

Scholar Rock Holding Corp (SRRK) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). $205 million cash proceeds from sale of Rare Pediatric Disease Priority Review Voucher to BioNTech.

Scholar Rock Holding Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $205 million cash proceeds from sale of Rare Pediatric Disease Priority Review Voucher to BioNTech
  • Voucher awarded after FDA approval of ISEMBYLD on September 11, 2026
  • Proceeds provide non-dilutive capital following ISEMBYLD approval
  • Closing remains subject to customary conditions, including HSR antitrust waiting-period expiration

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Scholar Rock’s financial and operating results for the quarter ended September 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1, the company’s earnings release

Item 7.01 · Regulation FD Disclosure

  • Conference call scheduled for November 10, 2026 at 8:00 a.m. ET
  • Slides cover financial and operating results for quarter ended September 30, 2026
  • Business update presentation furnished as Exhibit 99.2, requiring review for substantive metrics and catalysts

Item EX-99.1 · Exhibit EX-99.1

  • ISEMBYLD U.S. launch underway, generating $0.6 million Q3 revenue after September 11 FDA approval
  • Early demand broad across physicians and patients, but sustained treatment, reimbursement and market adoption remain key execution risks
  • Cash, equivalents and marketable securities $413.6 million at September 30, 2026, with an additional $205 million PRV sale pending
  • Q3 net loss $107.2 million versus $102.2 million, while R&D rose to $54.1 million and SG&A was $52.5 million
  • European MAA resubmitted and validated, with CHMP opinion targeted for H1 2027; Japanese application accepted under priority review

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 earnings update: ISEMBYLD U.S. launch underway, with initial inventory shipments generating $0.6 million
  • Early commercial reach: over one-third of Top 140 SMA centers prescribing, with demand across children and adults
  • ISEMBYLD-specific J-code expected April 1, 2027, potentially reducing reimbursement friction and prescription-to-infusion delays
  • Cash, equivalents and marketable securities totaled $413.6 million at September 30, 2026
  • Priority Review Voucher sale agreement adds $205 million upon closing, supporting launch, supply-chain and clinical investments

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Scholar Rock Holding Corp 8-K filings

Get the next SRRK 8-K as it lands

Follow SRRK for push alerts, or ask the research agent what this filing means.